Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Phase II Study of Sintilimab, Pegaspargase and Selinexor Followed by Radiotherapy in Newly Diagnosed Stage I/II Extranodal NK/T-Cell Lymphoma
Sponsor: Sun Yat-sen University
Summary
This is a single-arm, open-label, multicenter phase II study evaluating sintilimab, pegaspargase, and selinexor followed by radiotherapy as first-line treatment for patients with newly diagnosed stage I/II extranodal natural killer/T-cell lymphoma (ENKTL).
Official title: A Multicenter, Single-Arm, Phase II Study of Sintilimab, Pegaspargase and Selinexor Followed by Radiotherapy in Newly Diagnosed Stage I/II Extranodal NK/T-Cell Lymphoma
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
47
Start Date
2026-05-06
Completion Date
2031-05-06
Last Updated
2026-05-08
Healthy Volunteers
No
Conditions
Interventions
Sintilimab
Sintilimab will be given at 200 mg by intravenous infusion.
Pegaspargase
Pegaspargase will be given at 2000 U/m², with a maximum total dose of 3750 U, by intramuscular injection.
Selinexor
Selinexor will be given orally once weekly at 60mg.
radiotherapy
Patients will receive induction treatment for up to 4 cycles, followed by radiotherapy.
Locations (1)
Sun Yat-sen University Cancer Center
Guangzhou, 广东省 - Guangdong Sheng, China